Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

TMB-H Status Linked With High Responses to Dostarlimab in Endometrial Cancer

September 16th 2021

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

Olaparib Maintains Benefit Over Enzalutamide or Abiraterone in mCRPC

September 14th 2021

Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.

Enzalutamide/ADT Maintains Efficacy Regardless of Prior Antiandrogen Therapy in mHSPC

September 12th 2021

Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.

N-803/BCG Combo Shows Promising Responses, Tolerability in BCG-Unresponsive Bladder Cancer

September 10th 2021

Bacille Calmette-Guérin (BCG) plus N-803 yielded promising responses and an encouraging safety profile in patients with BCG-unresponsive, non-muscle invasive bladder cancer carcinoma in situ.

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma

September 10th 2021

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

Lurbinectedin/Doxorubicin Misses OS End Point in Relapsed SCLC, But Shows Superior Safety Vs SOC

September 9th 2021

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

Selpercatinib Elicits Durable Antitumor Activity in Advanced RET Fusion+ NSCLC

September 8th 2021

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

NEJM Data Underscore DFS Benefit With Adjuvant Pembrolizumab in Post-Nephrectomy RCC

September 7th 2021

Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE-564 trial.

Predictive Biomarkers for Checkpoint Inhibition Remain Unmet Need in HCC

September 3rd 2021

Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.

Single-Agent Trastuzumab Yields Superior Health-Related QoL in HER2+ Breast Cancer

September 3rd 2021

More detrimental effects on health-related quality of life were reported, and lasted for at least 12 months, with the combination of trastuzumab plus chemotherapy compared with trastuzumab alone in older patients with HER2-positive breast cancer, according to an analysis of the phase 3 RESPECT trial.

UV1 Vaccine Plus Pembrolizumab Shows Strong Safety, Early Activity in Metastatic Melanoma

September 2nd 2021

The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.

Rolling Submission of BLA to FDA Completed for Toripalimab Plus Chemotherapy in Metastatic Nasopharyngeal Carcinoma

September 1st 2021

The rolling submission of a biologics license application to support the approval of both toripalimab plus gemcitabine- and cisplatin-based chemotherapy as a first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, as well as toripalimab monotherapy for the second-line or beyond treatment of patients with recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemotherapy has been completed.

Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma

September 1st 2021

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

Biomarker Discovery and Testing Are Key to Improving Care for Early-Stage Resectable NSCLC

September 1st 2021

Jay M. Lee, MD, discusses the implications of the ADAURA trial in early-stage resectable NSCLC, the importance of molecular testing, and the need for a multidisciplinary approach in this population.

Black Men 97% Less Likely Than White Men to Receive Prostatectomy During COVID-19 Pandemic

August 31st 2021

During the height of the COVID-19 pandemic, Black patients were significantly less likely to undergo prostate cancer surgery compared with White patients, highlighting potential systemic inequities in care across medical specialties, and providing further rationale to recognize and the unintended diversion in cancer care due to the pandemic.

Increased Vitamin D Intake Associated With Lower Risk of Early-Onset CRC

August 25th 2021

Increased intake of vitamin D was associated with a decreased risk of early-onset colorectal cancer and precursors in younger women between the ages of 25 years and 42 years.

DFS Benefit Similar With Extended Intermittent or Continuous Letrozole in HR+ Breast Cancer

August 20th 2021

Extended adjuvant endocrine therapy via intermittent administration of letrozole did not improve disease-free survival vs continuous use in postmenopausal patients with hormone receptor–positive breast cancer, but represents a valid approach for those who require or prefer a treatment interruption.

EPOCH Trial Seeks to Establish the Role of TheraSphere Y-90 in Second-Line Metastatic CRC

August 20th 2021

Riad Salem MD, discusses previous data with TheraSphere™ Yttrium-90 in metastatic colorectal cancer, the potential role of this modality in the second-line setting, and future research directions.

Cancer Screenings Recover From Height of COVID-19 Pandemic, But Disparities Remain

August 19th 2021

Chris Labaki, MD, and Quoc-Dien Trinh, MD, discuss their research on the decline in cancer screenings during the height of the COVID-19 pandemic, the recovery of these tests, and potential existing disparities to be addressed.

Nivolumab Followed by TIL Therapy Shows Early Safety, Clinical Activity in Metastatic NSCLC

August 19th 2021

Nivolumab followed by treatment with tumor-infiltrating lymphocytes was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer.